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Renal function in general as well as many essential body functions and systemic 
parameters undergo pronounced circadian fluctuations [8]. Among these systems is 
mineral homeostasis where the concentration of calcium and phosphate in blood and 
hormones such as Parathyroid hormone (PTH), Fibroblast Growth Factor 23 (FGF23), 
and α-Klotho regulate mineral balance. 
Chronic kidney disease (CKD) is a devastating disease affecting mineral balance and 
leading eventually to phosphate overload with excessively increased morbidity and 
mortality due to cardiovascular disease (CVD) [13,14]. Elevated PTH, FGF23 and 
phosphate have been independently associated with cardiovascular disease in CKD 
and at least in the case of phosphate, evidence from experimental animal models and 
clinical studies is overwhelming to demonstrate a direct causal link between phosphate 
and mechanisms leading to CVD. 
Disordered mineral balance in kidney disease starts very early. During acute kidney 
injury (AKI) FGF23 rises rapidly and massively [6,2]. Similar in CKD, FGF23 rises very 
early and slowly when glomerular filtration rate (GFR) declines [11,9,4]. Also α-Klotho 
levels in kidney, circulation and urine fall and this may even precede the rise in FGF23. 
Also levels of calcitriol decrease progressively. Later in the progress of CKD, PTH 
increases and only in late stages also serum phosphate is elevated. At the same time, 
loss of circadian rhythms for plasma phosphate, calcium, PTH and FGF23 ensues. 
Neutralization of FGF23 with neutralizing antibodies has shown that FGF23 plays an 
important role in early kidney disease to protect against phosphate overload and CVD 
[12]. However, it has remained unclear what triggers the early rise of FGF23 as plasma 
phosphate levels tend to be rather low in early CKD. FGF23 is enzymatically degraded 
probably involving sortilin-like proteases, it may in part be cleared by renal excretion 
and both processes appear to be reduced in kidney disease. Moreover, we and others 
found that proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin 
1β (Il-1β) and Il-6 stimulate FGF23 production [7,5,3]. 
In this issue of Pflügers Archiv, Nordholm and colleagues add another facet to this 
puzzling picture [10]. They analyze the circadian fluctuations of various circulating 
parameters of mineral homeostasis together with activin A in normal rats and rats with 
reduced kidney function consuming different diets with increasing phosphate content. 
Their results not only confirm the loss or changes in circadian rhythmicity of important 
players in mineral homeostasis but they show that activin A levels are increased in 
animals with reduced kidney function, further increased by high phosphate intake, and 
that the circadian rhythm of activin A shows a reduced amplitude in CKD models.   
Why could this be of interest ?  
Activin A is a glycoprotein that either alone or after forming heterodimers together with 
activin B acts as endocrine factor. Initially recognized as a positive regulator for follicle-
stimulating hormone (FSH) release, it has become clear that particularly activin A 
plays many more roles in normal physiology and disease processes (for review see: 
[1]). Activin A belongs to the superfamily of transforming growth factor  (TGF-) and 
is signaling through ActRIIA/B receptors and Smads to alter transcription of target 


































































kidney where it is involved in branching morphogenesis and kidney repair, in brain 
where it has neuron-protective functions, and in heart and the vascular system where 
it controls cardiac myogenesis and cardiac remodeling. 
In kidney, activin A is produced by peritubular myofibroblasts activated during kidney 
disease and repair processes. It suppresses renal -Klotho levels which may be of 
importance as -Klotho is required for canonical FGF23 signaling and has been shown 
to exert protective effects on kidney and cardiovascular structures and functions. 
Activin A stimulates proliferation of fibroblasts and induces fibrosis at the same time 
inhibiting tubular cell proliferation and differentiation.  
Additional effects of activin A on skeletal muscle and bone may be important for our 
understanding of the mineral-bone-disorder in CKD patients (CKD-MBD). Activin A 
has negative effects on skeletal muscle recovery and proliferation. The effects of 
activin A on adult bone are controversial and activin A may have stimulatory effects 
on osteoblasts and bone mineralization as well as induce osteoclasts and reduce bone 
mineralization. Obviously, these processes are disturbed in CKD-MBD and whether 
activin A signaling may contribute remains to be clarified. Some of the controversial 
effects may be explained by altered circadian rhythms of hormones like PTH or activin 
A and the results reported by Nordholm and colleagues may promote further research 
in this direction.  
The recognition of activin A as an additional factor produced by the injured kidney and 
acting on target organs involved in the pathogenesis of CKD-MBD makes this an 
interesting molecule not only for our understanding of the disease but also as a 
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